Fosamprenavir/r vs atazanvir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Conference reports
Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young infants; interim results from the CHER study
3 September 2007. Related: Conference reports, Paediatric care.
Very low transmission rates among breastfeeding women receiving ART
3 September 2007. Related: Conference reports, Pregnancy.
Use of pre-exposure prophylaxis (PrEP) by sero-different couples wanting to conceive a child
3 September 2007. Related: Conference reports, Pregnancy.
Increased incidence of miscarriage with efavirenz use
3 September 2007. Related: Conference reports, Pregnancy.
No impact of HSV-2 suppressive therapy on HIV incidence
3 September 2007. Related: Conference reports.
Penile washing directly after sex increased the risk of acquiring HIV: circumcision effective for men in high prevalence populations no protective effect in gay men
3 September 2007. Related: Conference reports.
HBV or HCV coinfection produced higher risk from treatment interruptions: drug holidays and hepatitis dont mix
3 September 2007. Related: Conference reports, Hepatitis coinfection.
9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 19-21 July 2007, Sydney
3 September 2007. Related: Conference reports.
Can nevirapine be safely substituted for other agents in those with high CD4 cell counts and virologic suppression?
3 September 2007. Related: Conference reports.
Do children with perinatally acquired HIV infection have problems with metabolism and body shape?
3 September 2007. Related: Conference reports.
The growth hormone releasing factor analogue tesamorelin (TH9507) reduces visceral fat, but what else does it do?
3 September 2007. Related: Conference reports.
Does diabetes have the same impact on cardiovascular risk in HIV-positive patients as it does in the general population?
3 September 2007. Related: Conference reports.
Can nucleoside RT inhibitors directly cause insulin resistance?
3 September 2007. Related: Conference reports.
Do dyslipidemia, insulin resistance, and body shape changes differ according to race or ethnicity?
3 September 2007. Related: Conference reports.
Is lipoatrophy associated with vascular dysfunction?
3 September 2007. Related: Conference reports.
XVI International HIV Drug Resistance Workshop, 12-16 June 2007, Barbados
7 July 2007. Related: Conference reports.
Integrase inhibitors and resistance
7 July 2007. Related: Conference reports, Drug resistance.
Treatment failure and tropism changes in maraviroc trial related to previously undetected CXCR4, rather than a mutational shift from CCR5
3 July 2007. Related: Conference reports, Drug resistance.
Mechanisms of failure to CCR5 inhibitors is not explained by mutation in the V3 loop, cross-resistance between CCR5 inhibitors is likely
3 July 2007. Related: Conference reports, Drug resistance.
Higher risk of resistance using lopinavir/r monotherapy
3 July 2007. Related: Conference reports, Drug resistance.
Macaque study shows similar protection from rectal exposure using 2-hour pre- and 24-hour post exposure prophylaxis with tenofovir plus FTC compared to daily regimen
3 July 2007. Related: Conference reports, Drug resistance.
Thirteen NNRTI mutations linked to resistance to etravirine (TMC-125)
3 July 2007. Related: Conference reports, Drug resistance.
14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles
3 July 2007. Related: Conference reports.
Protease inhibitors in pregnancy
3 July 2007. Related: Conference reports, Women's health.
Low rates of HCV treatment among eligible injection drug users
3 July 2007. Related: Conference reports, Hepatitis coinfection.
Effect of HCV and HIV on mortality among injecting drug users
3 July 2007. Related: Conference reports, Hepatitis coinfection.
HCV/HIV-co-infected IDUs are at increased risk of death from hepatitis-related death in the HAART era, compared with HCV-mono-IDUs
3 July 2007. Related: Conference reports, Hepatitis coinfection.
Long-term effectiveness of isoniazid prophylaxis on TB incidence in a cohort of IDUs
3 July 2007. Related: Conference reports, TB coinfection.
The dynamics of HCV transmission among injection drug users in St. Petersburg
3 July 2007. Related: Conference reports.
Founder effect among HIV-positive IDU in Karachi, Pakistan
3 July 2007. Related: Conference reports.
8th International Workshop on Clinical Pharmacology of HIV Therapy, April 2007, Budapest, Hungary
3 July 2007. Related: Conference reports.
Drug-drug interactions
3 July 2007. Related: Conference reports, PK and drug interactions.
Pharmacokinetic data with existing antiretrovirals
3 July 2007. Related: Conference reports.
Antiretroviral pharmacokinetics in special patient populations
3 July 2007. Related: Conference reports.
Pharmacology of investigational drugs
3 July 2007. Related: Conference reports.
14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles
5 May 2007. Related: Conference reports.
No benefit of early cessation of breastfeeding in the Zambia Exclusive Breastfeeding Study (ZEBS)
4 May 2007. Related: Conference reports, Pregnancy.
Role of infant feeding and HIV in a severe diarrhoea outbreak in Botswana
4 May 2007. Related: Conference reports, Pregnancy.
Diarrhoea in uninfected infants of HIV-positive mothers who stop breastfeeding at 6 Months
4 May 2007. Related: Conference reports, Pregnancy.
Post-weaning gastroenteritis and mortality in HIV-uninfected infants receiving antiretroviral prophylaxis
4 May 2007. Related: Conference reports, Pregnancy.
Rates of diarrhoea associated with early weaning among infants in the Kisumu breastfeeding study
4 May 2007. Related: Conference reports, Pregnancy.
Early breastfeeding cessation among infants and risk of serious gastroenteritis: findings from a perinatal prevention trial in Kampala, Uganda
4 May 2007. Related: Conference reports, Pregnancy.
Treating children in resource-limited settings
4 May 2007. Related: Conference reports, Paediatric care.
Pharmacokinetics of nevirapine, d4T, and 3TC in Zambian children treated with Pedimune (Triomune)
4 May 2007. Related: Conference reports, Paediatric care.
New PK data for protease inhibitors
4 May 2007. Related: Conference reports, Treatment access, Paediatric care, Guidelines.
Plasma concentrations of efavirenz and lopinavir in children with and without rifampicin-based TB treatment
4 May 2007. Related: Conference reports, Paediatric care, TB coinfection.
NNRTI vs PI HAART regimens for children in resource-limited settings
4 May 2007. Related: Conference reports, Paediatric care.
Predictors of infant mortality
4 May 2007. Related: Conference reports, Paediatric care.
HIV-infection in the brain, neurocognitive dysfunction and CNS drug penetration
4 May 2007. Related: Conference reports.
Selected genetics studies from CROI
4 May 2007. Related: Conference reports.
Report from genomics workshop at CROI
4 May 2007. Related: Conference reports.
5th European HIV Drug Resistance Workshop, Cascais, Portugal, 29 March 2007
4 May 2007. Related: Conference reports.
Few integrase inhibitor (INI) mutations in INI-naive people
4 May 2007. Related: Conference reports, Drug resistance.
Response to darunavir, tipranavir, or lopinavir after atazanavir failure
4 May 2007. Related: Conference reports, Drug resistance.
Upper and lower clinical cutoffs proposed for darunavir
4 May 2007. Related: Conference reports, Drug resistance.
Accuracy of Monograms Trofile assay in determining tropism and new tropism assays in development
4 May 2007. Related: Conference reports, Drug resistance.
Several genotyping systems offer hope as tropism predictors
4 May 2007. Related: Conference reports, Drug resistance.
14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles
24 April 2007. Related: Conference reports.
Raltegravir (MK-0518) phase 3 trials show successful viral suppression in multi-drug resistant patients
4 April 2007. Related: Conference reports, Antiretrovirals, Drug resistance.
Maraviroc phase 2b/3 results in treatment experienced CCR5-tropic patients
4 April 2007. Related: Conference reports, Antiretrovirals.
Phase 2 study of Gileads integrase inhibitor elvitegravir (GS-9137)
4 April 2007. Related: Conference reports, Antiretrovirals.
Phase 2b study comparing rilpivirine (TMC-278) to efavirenz in treatment-naive patients: 48-week results
4 April 2007. Related: Conference reports, Antiretrovirals.
PK results from heat-stable formulation of ritonavir
4 April 2007. Related: Conference reports, Antiretrovirals.
Use of low-dose rapamycin, a CCR5 suppressant, to increase potency of T-20 in vitro
4 April 2007. Related: Conference reports, Antiretrovirals.